Good morning :)
$
₹
Oric Pharmaceuticals Inc

Oric Pharmaceuticals Inc

ORIC

NASDAQ
Asset Logo

Oric Pharmaceuticals Inc

ORIC

NASDAQ
$8.489.19% (-0.85)
$
₹
$8.489.19% (-0.85)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $994.0M the stock is ranked 2729

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.46
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.4
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 15 analysts reports

Buy
14 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+155.76%

Earnings Growth

+1.82%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 155.76% growth, versus a trailing 3-year CAGR of 7.16%.

2026
Current$8.49Baseline
Analyst Target - 1 year
Target$21.71+155.76%

All values in $

202220232024202520262027$9.95$14.59$19.24Target+155.76%
2026
Current$8.49Baseline
Analyst Target - 1 year
Target$21.71+155.76%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.52Baseline
Forecast for Dec 2026
High$-1.25+17.76%
Average$-1.49+1.82%
Low$-1.64-7.89%

All values in $

202120222023202420252026-2.07-2.25-1.96-1.82-1.52Low-7.89%Average+1.82%High+17.76%
2025
Current$-1.52Baseline
Forecast for Dec 2026
High$-1.25+17.76%
Average$-1.49+1.82%
Low$-1.64-7.89%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-32.5
-30.5
-35.7
-41.4
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0001.06000000
Net Income-25.01-31.96-34.56-36.30-30.02-36.35-32.58-30.50-35.76-41.49
Net Profit Margin----3405.90%------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Oric Pharmaceuticals Inc -2.46-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ORIC with any stock or ETF
Compare ORIC with any stock or ETF
Comparing from
ORIC
ABBV
AMGN
Loading...

Frequently asked questions

  1. Oric Pharmaceuticals Inc (ORIC) share price today is $8.48 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $9.32 and a day low of $8.48.

  2. Oric Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol ORIC.

  3. Oric Pharmaceuticals Inc's market capitalization is $994.02M as of November 6, 2026 at 2:29 AM IST.

  4. Oric Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Oric Pharmaceuticals Inc's price-to-book (P/B) ratio is 2.46 as of November 5, 2026.

  6. Yes, You can buy Oric Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Oric Pharmaceuticals Inc shares in three steps: 1. Search Oric Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Oric Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Oric Pharmaceuticals Inc (ORIC) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.1791 shares at the current price of $8.48.

Loading...